? France’s Innate Pharma has wooed AstraZeneca vet Jennifer Butler to lead the US operations it has set up after acquiring Lumoxiti from the British drugmaker in a rich add-on collaboration deal. Butler’s official title will be EVP and general manager of Innate Pharma US. Most recently, she was chief business officer, chief commercial officer and head of US operations at Tessa Therapeutics.
? Having handed off troubled microcap biotech Apricus Biosciences to Seelos Therapeutics via a merger, Richard Pascoe is moving on to his next CEO (and chairman) gig at Histogen. The regenerative medicine developer is anticipating data f… […]
From Agios to Deciphera, Steve Hoerter plots another oncology launch; Roche exec Christiane Hamachar moves to India as CEO of Biocon Biologics
? Deciphera $DCPH has scooped Agios’ chief commercial officer Steve Hoerter to fill retiring CEO Michael Taylor’s shoes. The Waltham, MA-based biotech is placing its trust in Hoerter’s sales acumen, especially for cancer drugs, acquired throughout his … […]
? Having built out a commercial footprint in the US and led the launch of Bavencio for Merck KGaA, David Trexler is taking up a new role as president of German biotech Morphosys’ US subsidiary. Following a dual listing on the Nasdaq $MOR last year, Mor… […]